EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Acadia Pharmaceuticals Inc. (ACAD) - Financial and Strategic SWOT Analysis Review

1 of 4
Acadia Pharmaceuticals Inc. (ACAD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Acadia Pharmaceuticals Inc. (Acadia) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Acadia’s lead product is Nuplazid (pimavanserin) is a FDA approved drug for the treatment of Parkinson’s disease psychosis. Its other pipeline products include pimavanserin for the treatment of schizophrenia and Alzheimer's disease psychosis; Adrenergic for chronic pain and Muscaninic for glaucoma. The company has partnerships with Allergen for the development of its drug candidates in the therapeutic areas of pain and ophthalmology. It has its operational presence with offices located in Denmark and Switzerland. Acadia is headquartered in San Diego, California, the US.

Acadia Pharmaceuticals Inc. Key Recent Developments

May 05, 2016: ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results
Feb 29, 2016: ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
Jan 25, 2016: ACADIA Pharmaceuticals Appoints James R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer
Jan 11, 2016: ACADIA Pharmaceuticals Appoints Jim Daly to Board of Directors
Dec 15, 2015: ACADIA Pharmaceuticals Appoints Julian C. Baker to Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Section 1 - About the Company

Acadia Pharmaceuticals Inc. - Key Facts

Acadia Pharmaceuticals Inc. - Key Employees

Acadia Pharmaceuticals Inc. - Key Employee Biographies

Acadia Pharmaceuticals Inc. - Major Products and Services

Acadia Pharmaceuticals Inc. - Pharmaceutical Pipeline Products Data

Acadia Pharmaceuticals Inc., Pipeline Products by Therapy Area

Acadia Pharmaceuticals Inc., Pipeline Products by Development Phase

Acadia Pharmaceuticals Inc. - History

Acadia Pharmaceuticals Inc. - Company Statement

Acadia Pharmaceuticals Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Acadia Pharmaceuticals Inc. - Business Description

Acadia Pharmaceuticals Inc. - Corporate Strategy

Acadia Pharmaceuticals Inc. - SWOT Analysis

SWOT Analysis - Overview

Acadia Pharmaceuticals Inc. - Strengths

Strength - Focused Research and Development

Strength - Lead Product: Nuplazid

Strength - Strong Patent Portfolio

Acadia Pharmaceuticals Inc. - Weaknesses

Weakness - Lack of Marketed Products

Acadia Pharmaceuticals Inc. - Opportunities

Opportunity - Market Potential: Parkinson’s Disease

Opportunity - Strong Product Pipeline

Opportunity - Changing Demographics

Acadia Pharmaceuticals Inc. - Threats

Threat - Intense Competition

Threat - Uncertain R&D Outcomes

Threat - Lack of Manufacturing Facilities

Threat - Stringent Government Regulations

Acadia Pharmaceuticals Inc. - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Acadia Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Acadia Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016

Acadia Pharmaceuticals Inc., Recent Deals Summary

Section 5 – Company’s Recent Developments

May 05, 2016: ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results

Feb 29, 2016: ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015

Jan 25, 2016: ACADIA Pharmaceuticals Appoints James R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer

Jan 11, 2016: ACADIA Pharmaceuticals Appoints Jim Daly to Board of Directors

Dec 15, 2015: ACADIA Pharmaceuticals Appoints Julian C. Baker to Board of Directors

Nov 30, 2015: ACADIA Pharmaceuticals Appoints Srdjan Stankovic, M.D., M.S.P.H., as Executive Vice President, Head of Research and Development

Nov 30, 2015: ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., to Board of Directors

Nov 05, 2015: ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results

Sep 03, 2015: ACADIA Pharmaceuticals Appoints Steve Davis as Chief Executive Officer

Aug 06, 2015: ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results

Section 6 – Appendix

Methodology

Ratio Definitions

About us

Contact Us

Disclaimer

List of Tables

Acadia Pharmaceuticals Inc., Key Facts

Acadia Pharmaceuticals Inc., Key Employees

Acadia Pharmaceuticals Inc., Key Employee Biographies

Acadia Pharmaceuticals Inc., Major Products and Services

Acadia Pharmaceuticals Inc., Number of Pipeline Products by Therapy Area

Acadia Pharmaceuticals Inc., Number of Pipeline Products by Development Stage

Acadia Pharmaceuticals Inc., Pipeline Products By Therapy Area and Development Phase

Acadia Pharmaceuticals Inc., History

Acadia Pharmaceuticals Inc., Subsidiaries

Acadia Pharmaceuticals Inc., Key Competitors

Acadia Pharmaceuticals Inc., Ratios based on current share price

Acadia Pharmaceuticals Inc., Annual Ratios

Acadia Pharmaceuticals Inc., Interim Ratios

Acadia Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Acadia Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016

Acadia Pharmaceuticals Inc., Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

Acadia Pharmaceuticals Inc., Pipeline Products by Therapy Area

Acadia Pharmaceuticals Inc., Pipeline Products by Development Phase

Acadia Pharmaceuticals Inc., Performance Chart (2011 - 2015)

Acadia Pharmaceuticals Inc., Ratio Charts

Acadia Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Acadia Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Note: Product cover images may vary from those shown
3 of 4
Pfizer AB
Novartis Pharmaceuticals Corporation
Cytogel Pharma, LLC
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll